THE 5-SECOND TRICK FOR TRASTUZUMAB ANNS

One of the most less than-investigated “driving forces” linked to trastuzumab resistance is PTEN. Nagata et al. (2004) described the lack of PTEN was observed in 36% of HER2-positive primary breast tumor specimens from people with phase IV condition. Moreover, In addition they confirmed that individuals with PTEN-deficient tumors experienced re